TPSTTempest Therapeutics, Inc.
1.511USD-1.93%Mkt Cap: 22.36M USDP/E: Last update: 2026-06-01

Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of pero…

Indicators:|

Key Statistics

Company
Market Cap22.36M USD
Enterprise Value26.68M USD
Revenue (TTM)
Gross Profit
Net Income (TTM)-26.26M USD
Revenue/Share
Last Price1.511 USD
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees4
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN
Valuation
P/E (Trailing)
P/E (Forward)-1.26
PEG
EV/EBITDA-1.01
EV/Revenue
P/S
P/B1.13
EPS (TTM)-5.70
EPS (Forward)-1.21
52W Range
1.5000% of range12.23
52W High12.23 USD
52W Low1.500 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-393.85%
ROA-155.11%
Growth
Revenue Growth
Earnings Growth
Cash Flow & Leverage
Operating CF-26.82M USD
CapEx (TTM)
FCF Margin
FCF Yield-78.65%
Net Debt434.00K USD
Net Debt/EBITDA-0.02
Balance Sheet
Debt/Equity1.22
Current Ratio2.50
Quick Ratio2.33
Book Value/Sh1.353 USD
Cash/Share0.5370 USD
Dividends
Fwd Div Rate
Trail. Div Rate0.0000 USD
Div. Yield
5Y Avg Yield
Payout Ratio0.00%
Ex-Div Date
Pay DateDec 10, 2018
Splits
Last Split1:13
Split DateApr 9, 2025
Analyst Consensus
Rating
Target (Mean)11.00 USD
Target Range11.00 USD11.00 USD
# Analysts1
Ownership
Shares Out.14.81M
Float9.27M
Insiders34.26%
Institutions28.49%
Short Interest
Short Ratio1.4d
Short % Float6.85%
Short % Out.2.75%
Shares Short395.02K
Short (prev mo.)449.00K
Technical
SMA 501.855 (-18.5%)
SMA 2005.087 (-70.3%)
Beta-1.69
S&P 52W Chg27.70%
Avg Vol (30d)139.53K
Avg Vol (10d)113.79K
Technical Indicators
RSI (14)35.7
MACD-0.0610
MACD Signal-0.0322
MACD Hist.-0.0288
BB Upper2.188 USD
BB Middle1.896 USD
BB Lower1.603 USD
BB Width30.86%
ATR (14)0.1503 USD
Vol Ratio (20d)1.69x